A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Lymphoma - FIL_FOLL12

FONDAZIONE ITALIANA LINFOMI ONLUS0 个研究点开始时间: 2012年8月2日最近更新: 2013年7月15日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Histological diagnosis of B-Cell CD20+ Follicular Lymphoma (FL), grade I, II, IIIa according to the WHO 2008 classification • ECOG performance status 0-2 • Age = 18 years • Ann Arbor stage II-IV • FLIPI2>0 • Presence of evaluable/measurable disease after diagnostic biopsy • At least one of the following criteria for defining active disease: - systemic symptoms - cytopenia due to bone marrow involvement - LDH> upper normal value - any nodal or extranodal tumor mass with a diameter >7cm - involvement of = 3 nodal sites, each with a diameter of = 3cm - extranodal disease - rapidly progressive disease • Life expectancy > 6 months • Left ventricular ejection fraction (LVEF) ? 50% • Serum negativity for HIV • Serum negativity for HBsAg; HBcAb positive but HBV-DNA negative patients are allowed with mandatory Lamivudine prophylaxis. • Serum negativity for HCV, except for those patients without signs of active viral replication assessed by HCV-RNA copies • Serum creatinine < 2mg/dl , serum bilirubin < 1.5mg/dl, aspartate amino-transferase (AST/GOT) ? 2.5xUNV, alanine amino-transferase (ALT/GPT) ? 2.5xUNV, and alkaline phosphatase ? 4 times the upper limit of normal (unless the increase is attributed directly to the presence of tumour by the Investigator) • Patients with no previous treatment for the lymphoma with the exception of locoregional radiotherapy (IF-RT) • Adequate measure adoption to avoid pregnancy • Written informed consent given at time of registration • Patient must be accessible for treatment and follow up
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 400
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 202

排除标准

•Histological diagnosis of : -any lymphoma other than follicular lymphoma and all CD20 negative B-cell lymphomas -grade III b follicular lymphoma -evidence of transformation to high grade lymphoma • Ann Arbor stage I • Suspect or clinical evidence of CNS involvement by lymphoma • History of other malignancies within 5 years prior to study entry except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer, low grade, early stage localized prostate cancer treated surgically with curative intent, good prognosis DCIS of the breast treated with lumpectomy alone with curative intent • Evidence of any severe active acute or chronic infection • Concurrent co-morbid medical condition which might exclude administration of full dose chemotherapy • Severe chronic obstructive pulmonary disease with hypoxemia • Severe diabetes mellitus difficult to control with adequate insulin therapy • Myocardial infarction within 6 months before study entry • Clinically significant secondary cardiovascular disease e.g. uncontrolled hypertension, (resting diastolic blood pressure >115 mmHg), uncontrolled multifocal cardiac arrhythmias, symptomatic angina pectoris or congestive cardiac failure NYHA class III-IV • HbsAg-positive, HIV-positive, or HCVAb-positive patients • Known hypersensitivity or anaphylactic reactions to murine antibodies or proteins • Any other co-existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent • Follicular lymphoma, showing a negative baseline PET scan

研究者

发起方

FONDAZIONE ITALIANA LINFOMI ONLUS

相似试验

进行中（未招募）

不适用

EUCTR2006-002703-13-ATHuman Genome Sciences, Inc.1,290

进行中（未招募）

1 期

EUCTR2006-002703-13-FRHuman Genome Sciences, Inc.

进行中（未招募）

1 期

EUCTR2006-002704-34-FRHuman Genome Sciences, Inc.

进行中（未招募）

1 期

A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNa2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 2 or 3. ACHIEVE-2/3Estudio multicéntrico, aleatorizado, de fase 3, dirigido a evaluar la eficacia y seguridad de la albúmina interferón alfa-2b (alb-IFN) combinada con ribavirina en comparación con peginterferón alfa-2a (PEGASYS or peg-IFNa2a) combinado con ribavirina en sujetos con hepatitis C crónica, genotipo 2-3, no tratados anteriormente con interferón alfa. ACHIEVE-2/3 - ACHIEVE-2/3Chronic Hepatitis C (CHC) genotype 2/3.MedDRA version: 8.0Level: LLTClassification code 10008912

EUCTR2006-002704-34-ESHuman Genome Sciences, Inc.

进行中（未招募）

1 期

EUCTR2006-002703-13-GBHuman Genome Sciences, Inc.